Cover Image

From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

Emilio Bajetta, Giuseppe Procopio, Sara Pusceddu, Filippo Pietrantonio, Massimo Milione, Marco Maccauro, Elena Verzoni, Valentina Guadalupi, Marco Platania
  • Giuseppe Procopio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy
  • Sara Pusceddu
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy
  • Filippo Pietrantonio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy
  • Massimo Milione
    Pathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • Marco Maccauro
    Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • Elena Verzoni
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy
  • Valentina Guadalupi
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy
  • Marco Platania
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy

Abstract

Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

Keywords

Neuroendocrine tumours - Angiogenesis - Metastasis - Chemotherapy - Target therapy

Full Text

FULL TEXT
Submitted: 2011-12-13 14:12:33
Published: 2011-12-14 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
549

Views:
FULL TEXT
93

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Emilio Bajetta, Giuseppe Procopio, Sara Pusceddu, Filippo Pietrantonio, Massimo Milione, Marco Maccauro, Elena Verzoni, Valentina Guadalupi, Marco Platania

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185